US OptionsDetailed Quotes
AKBA250117C1500
- 0.55
- 0.000.00%
15min DelayTrading Jan 17 16:00 ET
0.00High0.00Low
0.00Open0.55Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV-14.19%PremiumJan 17, 2025Expiry Date0.89Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Akebia Therapeutics Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...
57
11
4
$Akebia Therapeutics (AKBA.US)$ 👇👇👇 double bottom. Today is breakout day
1
$Akebia Therapeutics (AKBA.US)$ thhis is it.
$Akebia Therapeutics (AKBA.US)$ ..Don’t sell!! hold
$Akebia Therapeutics (AKBA.US)$
Akebia Therapeutics Announces Multiple Positive Business Updates
Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.
Market research indicates strong physician interest, with 99% of n...
Akebia Therapeutics Announces Multiple Positive Business Updates
Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.
Market research indicates strong physician interest, with 99% of n...
2
1
$Akebia Therapeutics (AKBA.US)$ Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025
Benzinga· 2 mins ago
New Commercial Supply Contracts for Vafseo (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S.
Vafseo tablets now shipping in the U.S.
Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo...
Benzinga· 2 mins ago
New Commercial Supply Contracts for Vafseo (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S.
Vafseo tablets now shipping in the U.S.
Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo...
1
$Akebia Therapeutics (AKBA.US)$ Double bottom 👌 i get it.
2
1
$Akebia Therapeutics (AKBA.US)$ .. Why drop due to earning report ??
$Akebia Therapeutics (AKBA.US)$ all good
5
No comment yet
103851773 : what means of possible swing bro?
Jaguar8 OP 103851773 : Swing means possible hold for January
70108039 103851773 : don't listen to anybody listen to yourself only
103851773 Jaguar8 OP : okay, thanks ya.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
GG4WIN : AH mean, sorry not too gd w short form? txs for your detail analysis and i will recommend you to others for follows
View more comments...